Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912250042> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2912250042 endingPage "e1" @default.
- W2912250042 startingPage "e1.1" @default.
- W2912250042 abstract "Objectives To assess the safety and efficacy of SFX-01 after subarachnoid haemorrhage. Design SFX-01 is a synthetic agent that contains sulforaphane that has been shown to be neuroprotective in animal models of subarachnoid haemorrhage. This is a phase II double-bilinded, placebo-controlled randomised clinical trial. Subjects Target of 90 patients with fisher 3 or 4 subarachnoid haemorrhage. Methods Patients admitted to the three recruiting centres within 48 hours of ictus will be randomly allocated to placebo or SFX-01. The randomisation is stratified into WFNS 1–3 or 4–5. Participants will receive the trial medication in a capsule format twice-daily for 28 days. Patients will have transcranial dopplers (TCD) on alternate daily basis for at least 7 days. The maximum mean MCA flow velocity as well as safety are the two primary end-points. All patients will have paired blood and CSF taken at day 7 either through an LP or via EVD sampling. Follow-ups are performed at day 28, 3 months and 6 months which include safety bloods, functional questionnaires, mRS, GOSE and MRI. Results 64 (71% of the target) patients have been enrolled. 35 patients have completed the study. Statistical analysis of the TCD data will be performed at the end of the trial. The mortality is at 9.5% (6). DSMB have met twice since the start of the trial and there have been no safety concerns. Conclusions The trial is recruiting on the planned trajectory and at this rate we are projected to complete the trial by the end of the year." @default.
- W2912250042 created "2019-02-21" @default.
- W2912250042 creator A5023662367 @default.
- W2912250042 creator A5038952654 @default.
- W2912250042 creator A5065953606 @default.
- W2912250042 creator A5066197980 @default.
- W2912250042 date "2019-02-14" @default.
- W2912250042 modified "2023-09-23" @default.
- W2912250042 title "WM1-2 SFX-01 after subarachnoid haemorrhage: protocol of a multi-centre, phase II, double-blinded, randomised controlled trial" @default.
- W2912250042 doi "https://doi.org/10.1136/jnnp-2019-abn.1" @default.
- W2912250042 hasPublicationYear "2019" @default.
- W2912250042 type Work @default.
- W2912250042 sameAs 2912250042 @default.
- W2912250042 citedByCount "0" @default.
- W2912250042 crossrefType "journal-article" @default.
- W2912250042 hasAuthorship W2912250042A5023662367 @default.
- W2912250042 hasAuthorship W2912250042A5038952654 @default.
- W2912250042 hasAuthorship W2912250042A5065953606 @default.
- W2912250042 hasAuthorship W2912250042A5066197980 @default.
- W2912250042 hasConcept C126322002 @default.
- W2912250042 hasConcept C141071460 @default.
- W2912250042 hasConcept C142724271 @default.
- W2912250042 hasConcept C168563851 @default.
- W2912250042 hasConcept C203092338 @default.
- W2912250042 hasConcept C204787440 @default.
- W2912250042 hasConcept C27081682 @default.
- W2912250042 hasConcept C2776098176 @default.
- W2912250042 hasConcept C2777736543 @default.
- W2912250042 hasConcept C2992083352 @default.
- W2912250042 hasConcept C42219234 @default.
- W2912250042 hasConcept C44249647 @default.
- W2912250042 hasConcept C535046627 @default.
- W2912250042 hasConcept C71924100 @default.
- W2912250042 hasConceptScore W2912250042C126322002 @default.
- W2912250042 hasConceptScore W2912250042C141071460 @default.
- W2912250042 hasConceptScore W2912250042C142724271 @default.
- W2912250042 hasConceptScore W2912250042C168563851 @default.
- W2912250042 hasConceptScore W2912250042C203092338 @default.
- W2912250042 hasConceptScore W2912250042C204787440 @default.
- W2912250042 hasConceptScore W2912250042C27081682 @default.
- W2912250042 hasConceptScore W2912250042C2776098176 @default.
- W2912250042 hasConceptScore W2912250042C2777736543 @default.
- W2912250042 hasConceptScore W2912250042C2992083352 @default.
- W2912250042 hasConceptScore W2912250042C42219234 @default.
- W2912250042 hasConceptScore W2912250042C44249647 @default.
- W2912250042 hasConceptScore W2912250042C535046627 @default.
- W2912250042 hasConceptScore W2912250042C71924100 @default.
- W2912250042 hasIssue "3" @default.
- W2912250042 hasLocation W29122500421 @default.
- W2912250042 hasOpenAccess W2912250042 @default.
- W2912250042 hasPrimaryLocation W29122500421 @default.
- W2912250042 hasRelatedWork W1608246717 @default.
- W2912250042 hasRelatedWork W2028584578 @default.
- W2912250042 hasRelatedWork W2057382651 @default.
- W2912250042 hasRelatedWork W2113848764 @default.
- W2912250042 hasRelatedWork W3106862589 @default.
- W2912250042 hasRelatedWork W3200621203 @default.
- W2912250042 hasRelatedWork W4220675698 @default.
- W2912250042 hasRelatedWork W4221026952 @default.
- W2912250042 hasRelatedWork W4243003639 @default.
- W2912250042 hasRelatedWork W4306253774 @default.
- W2912250042 hasVolume "90" @default.
- W2912250042 isParatext "false" @default.
- W2912250042 isRetracted "false" @default.
- W2912250042 magId "2912250042" @default.
- W2912250042 workType "article" @default.